Dipeptidyl peptidase-4 (DPP-4) inhibitors are widely used as antidiabetic drugs. We recently reported that DPP-4 inhibition has beneficial effects on heart failure (HF) mice model. Furthermore, we confirmed that myocardial DPP-4 activity was significantly increased in HF mice compared with non-HF mice. The aim of this study was to investigate the level of myocardial CD26 (DPP-4) expression and its association to clinical parameters in HF patients.
H eart failure (HF) is still one of the leading causes of death in many countries. 1, 2) Despite the numerous clinical studies on HF, the precise mechanisms of HF development are not fully understood. To provide exact medical care, it is important to predict the prognosis of HF patients. Currently, risk stratification for patients with nonischemic HF is always based on clinical parameters, such as the New York Heart Association class; echocardiographic parameters, such as left ventricular ejection fraction (LVEF); and blood markers, such as the level of a 76-amino acid N-terminal fragment in the prohormone called B-type natriuretic peptide (NTproBNP) and brain natriuretic peptide (BNP). 3, 4) Endomyocardial biopsy (EMB) has been used to diagnose specific diseases in patients with nonischemic HF, such as dilated and hypertophic cardiomyopathy, amyloidosis, myocarditis, Fabry disease, and sarcoidosis. 5, 6) Morphologic abnormalities (e.g., cardiomyocyte size), area of the cardiomyocyte nucleus, myofibril volume fraction, interstitial volume density, extent of extracellular matrix (ECM), and fibrosis area in the myocardium are factors that need to be observed. Moreover, there may be molecular alterations in EMB specimens that might serve as sensitive and specific markers of the outcome in HF patients. TUNEL staining and Ki-67 in EMB samples are reported to be useful to predict prognosis. 7) The expression level of CyPA 8) and Gremlin-1 9) has been shown to predict bad outcomes in heterogeneous HF patient populations. Ubiquitin staining is reported to be correlated with bad outcome, 10) and high hnRNP-C staining might predict good outcome in HFrEF patients. A Japanese group recently reported that the aberrant activation of the mammalian/mechanistic target of rapamycin complex 1 in cardiomyocytes was associated with myocardial fibrosis and worse prognosis in patients with non-ICM HF. 11) Moreover, increased myocardial tenascin-C expression was reported to be associated with worse LV remodeling and long-term outcome in dilated cardiomyopathy (DCM) patients. 12) These results suggest that the activation/expression of various molecules might have the possibility to Kobara, ET AL predict the prognosis of HF patients. Myocardial ECM plays an important role in maintaining the structure of myocytes and blood vessels to strengthen myocardial tissue. 13) Cardiac fibrosis is one of the detrimental factors that contribute to HF during pressure overload conditions such as hypertension or aortic valve stenosis. The increased accumulation of fibrosisrelated proteins in the interstitium myocardium and perivascular areas has been implicated in the pathogenesis of HF. 14) Collagen deposition in response to myocyte loss is a replacement process, but the increased accumulation of collagen leads to HF. The resultant reactive fibrosis contributes to increased myocardial stiffness, 15) electrical resistance, and diastolic dysfunction of the heart. Furthermore, paracrine secreted by profibrotic fibroblasts may often deteriorate the function of cardiomyocytes. Cardiovascular magnetic resonance (CMR) imaging using late gadolinium enhancement is a useful tool for evaluating the extent of myocardial fibrosis. The extent of myocardial fibrosis determined by CMR can be used to estimate the prognosis of HF patients. 16 ) However, little is known about the correlation between the outcome of HF patients and the extent of myocardial fibrosis calculated directly from biopsy specimens in HF patients. Myocardial collagen volume SIGNIFICANCE OF DPP-4 EXPRESSION ON FAILING HEART Figure 1 . Relationship between the %fibrosis area or CD26 density in the myocardium and the BNP levels at one year after EMB. A: Relationship between %fibrosis area and BNP levels at EMB. B: Relationship between %fibrosis area and BNP levels at one year after EMB. C: Relationship between CD26 density and BNP levels at EMB. D: Relationship between CD26 density and BNP levels at one year after EMB. *P < 0.05 as determined by Student's t-test. fraction evaluated on biopsy samples has recently been reported as a useful indicator for all-cause death and cardiac events in HFrEF patients but not in HFpEF patients. 17) Patients with diabetes were more likely to develop CHF than patients without diabetes. 18, 19) Given that the primary mortality risk of diabetes is cardiovascular disease, 20) the prevention of HF is an important therapeutic strategy for diabetes patients. Dipeptidyl peptidase-4 (DPP-4)/ CD26 inhibitors are a new class of antidiabetic drugs that block DPP-4 enzyme activity. 21) CD26 has a dual function as a regulatory protease and a binding protein. 22) CD26 is expressed by the epithelial cells of the gut, liver, and kidney. 23) As DPP-4 degrades and inactivates incretin hormones such as glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide, DPP-4 inhibitors lower blood glucose levels via incretin hormones. Many studies have reported that DPP-4 inhibitors have protective effects on various organs including the pancreas, kidney, brain, and heart. 24) There have also been several papers that demonstrate the cardioprotective effects of DPP-4 inhibitors. [24] [25] [26] [27] [28] [29] Those papers reported that DPP-4 inhibitors increase GLP-1 and stromal cell-derived factor-1α (SDF-1α), which is also a substrate of DPP-4 and produces its effects through its receptor CXCR4 (CXC chemokine receptor 4), 30) thus contributing to the protective effects of DPP-4 inhibitors. Antiapoptosis and angiogenesis are recognized in heart treated by DPP-4 inhibitors. 29) Our group recently reported that DPP-4 inhibition has direct protec-Kobara, ET AL tive effects on post-MI heart by inducing an antiapoptotic effect and inhibiting a decrease in vessel number via the SDF-1α/CXCR4-mediated STAT3 signaling pathway. 31) Furthermore, we confirmed that myocardial DPP-4 activity was significantly increased in HF mice compared with non-HF mice.
The aim of this study was to investigate the level of myocardial CD26 expression and its association to clinical parameters in HF patients.
Methods

Subjects:
In this study, we enrolled 45 consecutive patients with nonischemic HF (LVEF < 60%) patients who underwent right or left ventricular EMB from June 2006 to July 2012 at Chiba University Hospital. Patients who were not followed up at Chiba University Hospital for 1 year after EMB were excluded (n = 10). Patients who were diagnosed with takotsubo cardiomyopathy (n = 1) and are underage (< 20 years old, n = 1) were also excluded. Finally, 33 patients with HF were enrolled in this study. The myocardium of two patients who were decreased by noncardiac disease was used as Control. For each patient, we collected clinical, hemodynamic, and blood test data at one year after EMB, and the data were analyzed. The blood BNP level and serum creatinine (Cre) in one patient who was treated by chronic hemodialysis was excluded. The average follow-up periods of 33 patients were 11.6 ± 2.0 months. This study was performed according to the Declaration of Helsinki and was approved by the ethics committee of our institution (no informed consent was required). in two to five different, randomly selected, high-power fields by EMB. 12) To determine the levels of myocardial fibrosis, we calculated the ratio of the fibrosis area stained with Masson's trichrome to the total myocardium area by using BZ-X Analyzer (KEYENCE, Osaka, Japan). The ratio of the total blue-stained area without endocardium to the whole myocardial area in Masson's trichrome-stained sections was calculated and defined as %fibrosis area. By using the median %fibrosis area (20.49%), all patients were divided into two groups: a high %fibrosis area (Fb-H) group and a low %fibrosis area (Fb-L) group. 11) To determine the degree of CD26 density, the biopsy samples were immunostained with antihuman CD26 antibody, followed by antirabbit HRP (Jackson ImmunoResearch Laboratories, PA, USA) and DAB Peroxidase Substrate kit (Vector Laboratories, CA, USA). First, we tested randomly selected heart samples of the patients and noncardiac disease controls. We examined DAB exposure time in which endothelial cells (as an internal positive control) were moderately stained, and the myocardium in noncardiac disease control was not stained. Finally, we decided a DAB exposure time of 50 seconds in all samples throughout this study. CD26 density was calculated as "the sum of the intensity levels of CD26 staining per pixel in the area of myocardium"/"total area of myocardium") by using BZ-X Analyzer (Keyence, Osaka, Japan). The negative control staining was performed in the same manner without the first antibody. By using median CD26 density (26.98/pixel), all patients were divided into two groups: a high CD26 density (CD26-H) group and a low CD26 density (CD26-L) group. 11) Fibrosis area and CD26 density were quantitatively analyzed in a blinded manner. Statistics: All data were presented as mean ± SD. The differences in data between groups were tested by Student's t-test or Fisher's exact test. Pearson's correlation analysis was performed to estimate the correlations between CD26 density and %fibrosis area. 11) We performed univariate and multivariate regression analyses to determine the factors associated with blood BNP levels at one year after EMB. The difference was considered significant if the P-value was < 0.05. Statistical analysis was performed using Statcel3 software (OMS Publishing, Saitama, Japan).
Results
Patient clinical characteristics:
A total of 33 consecutive HF patients were diagnosed with DCM, myocarditis, and other cardiac diseases. We divided them into three groups for analysis: Total group (n = 33), HF group with reduced ejection fraction (HFrEF; LVEF < 40%, n = 19), and DCM group (pathological diagnosis, n = 24) according to the ESC 2016 HF guideline. 32) There were no differences in age, gender, family histories, treatments, echocardiographic parameters, and hemodynamic parameters at EMB between the Fb-H group and Fb-L group in total and HFrEF patients (Table I) . By contrast, blood BNP levels at EMB were higher in the Fb-H group than in the Fb-L group in HFrEF patients ( Figures 1A, 2A ). There were no significant differences in age, gender, family history, treatment, echocardiographic parameters, hemodynamic parameters, and blood BNP levels at EMB between the CD26-H group and CD26-L group in the Total group (Table I and Figure 1B) .
Fibrosis area in myocardium:
The representative images of Masson's trichrome-stained sections were shown in Figure 1A . The %fibrosis area ranged from 6.14% to 62.55%. Quantitative analysis showed that the %fibrosis area was approximately threefold higher in the HF group than in the Control group (Control; 7.2% versus HF; 22.75 ± 12.46%) ( Figure 2C ). Furthermore, there were no significant differences between the %fibrosis area and echocardiographic parameters at one year after EMB (Table II). Figure 1B shows the representative images of CD26-stained histological sections. The stains of CD26 were detected in the cellular membrane and cellular cytoplasm in cardiomyocytes and Kobara, ET AL endothelial cells in the HF group, but there were few CD26 signals in the interstitium and fibrosis area. Moreover, few CD26 signals were also detected in the Control group. Quantitative analysis showed that the index of CD26 density levels were approximately 12-fold higher in the HF group than in the Control group (3.31/pixel versus 40.22 ± 41.90/pixel) ( Figure 1D ). Furthermore, CD26 density levels were positively correlated with %fibrosis area in the Total group, HFrEF patients, and DCM patients (Figure 3) . Furthermore, there were no significant differences between the %fibrosis area and echocardiographic parameters at one year after EMB ( Table II) .
CD26 expression in myocardium:
Given that the blood BNP levels at EMB were not different between the CD26-L group and CD26-H group, blood BNP levels at one year after EMB were significantly increased in the CD26-H group compared with the CD26-L group in the Total group and DCM patients ( Figure 1D ). These results suggested that the levels of CD26 density were positively correlated with blood BNP levels at one year after EMB. Correlations between CD26 staining and blood BNP levels at one year after EMB: Univariate and multivariate regression analysis were performed to determine the correlation of various factors to blood BNP levels at one year after EMB. CD26 density, BUN, and Cre were significant predictive values to blood BNP levels at one year after EMB by univariate regression analysis (Table III) . On the basis of multivariate regression analysis using BUN, Cre, %fibrosis area, and CD26 density, only CD26 density was shown to be an independent determinant of blood BNP levels at one year after EMB (Table III) . There were no HF hospitalization in the CD26-L and CD26-H groups, but one patient died owing to unknown reasons, and one patient received radiofrequency catheter ablation therapy. Furthermore, one patient in the CD26-H group was implanted with an implantable cardioverter defibrillator during one year after EMB.
Discussion
The novel findings of this study are as follows: (1) CD26 density in the myocardium is significantly associated with the degree of myocardial fibrosis; (2) %area of myocardial fibrosis are significantly related to the blood BNP levels at EMB in HFrEF patients; (3) CD26 density in the myocardium is significantly related to the level of blood BNP levels at one year after EMB. Thus, we confirmed that the level of myocardial CD26 expression might be a predictive marker in HF patients.
In this study, we confirmed that there is a significant correlation between CD26 expression level and the extent of myocardial fibrosis in the myocardium of HF patients. During LV remodeling, cardiac fibroblasts differentiated into myofibroblasts that synthesize and release various cytokines to replace the composition of ECM. Myocardial fibroblasts have been reported to be involved in the pathologies of the progression of cardiac fibrosis. Therefore, the intervention to the mechanisms of myocardial fibrosis is thought to be an effective strategy for treating and preventing HF. Transforming growth factor-β1 (TGF-β1) is a cytokine that acts on fibroblasts to differentiate them into myofibroblasts. Although the detailed mechanisms by which DPP-4 inhibition ameliorates the progression of myocardial fibrosis in failing heart are still unknown, several papers reported that DPP-4 inhibition decreases TGF-β1 expression. 33, 34) We speculated that DPP-4 inhibition decreased TGF-β1-induced collagen synthesis and fibrogenesis in the myocardium. Moreover, we recently published data on the effects of CD26 on type III collagen expression in the early phase of failing heart. 35) CD26 in the myocardium may have been involved in the pathophysiological mechanisms of myocardial fibrosis by inducing type III collagen expression. Values are means ± SD. BNP indicates brain natriuretic peptide; LAD, left atrial diameter; IVSTd, interventricular septal thickness at end-diastole; PWTd, posterior wall thickness at end-diastole; LVDd, left ventricular diameter at end-diastole; LVDs, left ventricular diameter at end-systole; LVEF, left ventricular ejection fraction; E/A, early/atrial diastolic mitral flow velocity ratio; DcT, deceleration time; E/e', early mitral inflow velocity to diastolic mitral annular velocity; TRPG, tricuspid regurgitation pressure gradient; IVC, diameter of the inferior vena cava; WBC, white blood cell; Hb, hemoglobin; BUN, blood urea nitrogen; Cre, creatinine; CRP, c-reactive protein; PCWP, pulmonary capillary wedge pressure; CO, cardiac output; and CI, cardiac index. *P < 0.05. † P < 0.001.
SIGNIFICANCE OF DPP-4 EXPRESSION ON FAILING HEART
Considering that DPP-4 inhibitors have been reported to have anti-inflammatory effects, DPP-4 inhibitors could have indirect beneficial effects on cardiac function by inhibiting inflammation in the myocardium. 36) DPP-4 is a serine protease that cleaves a dipeptide from the Nterminus of incretin. It has been reported that DPP-4 degrades and inactivates many other substrates other than incretin. 37 ) GLP-1 is the substrates of DPP-4 and binds to GLP-1R, thus resulting in the cAMP-protein kinase Amediated suppression of nuclear factor (NF)-kB. 36) The inactivation of GLP-1 by CD26 prevents GLP-1R-induced inflammation via the activation of NF-kB signaling on antigen presentation cells. The mechanism by which CD26 may potentiate inflammation in T2DM likely involves both its catalytic and noncatalytic function. In addition to its well-known peptidase activity, CD26 also possesses noncatalytic functions via its interaction with ligands including ADA, caveolin-1 (Cav-1), fibronectin, and CXCR4. 36) There is good evidence suggesting the role of DPP-4 noncatalytic function in the regulation of T-cell activation. [38] [39] [40] CD26 is an activation marker of human CD4 (+) T cells and is associated with T-cell signal transduction processes as a costimulatory molecule. The CD26 costimulation pathway in CD8(+) T cells is distinct from the CD28 costimulation pathway. 39) Recently, Hiromura, et al. 41) reported that Cav-1, which is a major structural protein of caveolae located on the surface of the cellular membrane, is a target molecule for DPP-4 inhibitors in the suppression of TLR4-mediated inflammation in mouse and human macrophages. The DPP-4 activity site is located in the extracellular domain of CD26 protein. CD26 molecule was partially cleaved, and substantial DPP-4 activity was also found in plasma and other body fluids because the soluble form of DPP-4 (sDPP-4) lacks the cytoplasmic tail and transmembrane region. 42) sDPP-4 directly and markedly activates the MAPK-and NF-κB signaling pathway in a protease-activated receptor 2 dependent manner, thus leading to proatherogenic changes in human vascular smooth muscle cells. 43) DPP-4 can also regulate chronic stress-induced bone marrow hematopoietic stem cells activation and inflammatory cell production via an Adrβ3 (β3-adrenergic receptor)/CXCL12 (C-X-C motif chemokine 12)-dependent mechanism, thus suggesting that DPP-4 inhibition may have applications for treating inflammatory diseases.
44) DPP-4 expression increases with the functional maturation of dendritic cells and macrophages from monocytes with a role for the upregulation of CD86 expression and activation of the NF-κB pathway. 40, 45, 46) Given the limitation in the available sample volume of EMB specimen in the present study, we could not perform immunochemical analysis on the infiltrated cells in the failing myocardium. CD26 may regulate inflammatory response via multiple mechanisms that involve both adaptive and innate immune function. Currently, we are investigating the mechanisms implicated in the inhibitory effects of DPP-4 inhibition on myocardial inflammation Kobara, ET AL and fibrosis by using cultured cardiac myofibroblast model.
In this study, we confirmed that the intensity of CD26 staining is significantly related to the level of blood BNP at one year after EMB. We detected CD26 immunostaining levels not only in the cell membrane but also in the cytoplasm of the cardiomyocyte. There was a report describing the localization of CD26 in the cytoplasm and nucleus in human cancer cells. 47) The stained area in the cytoplasm may detect the process of breaking and recycling of CD26 molecule after cleavage, but its mechanism have not been identified. Blood BNP, which is produced by cardiomyocytes in the failing heart, 48) is recognized as good biomarkers for diagnosing HF patients 49) and has cardioprotective effects. BNP1-32 and NT-proBNP are cleaved from the 108-amino acid prohormone BNP. 50) BNP1-32 is degraded at two N-terminal amino acids (Ser Pro) to BNP3-32 by DPP-4, and BNP3-32 show reduced biological activity compared with BNP1-32.
51) It has been reported that circulating BNP1-32 is absent in advanced-stage HF patients. 52) We speculated that increased CD26 activity in the heart increased the local concentration of BNP3-32, thus antagonizing the binding of BNP1-32 to the natriuretic peptide receptor-A (Figure 4) . Considering that the clinical laboratory test could not distinguish BNP3-32 from BNP1-32, further studies are needed to investigate the roles of CD26, BNP1-32, and BNP3-32 in the failing heart.
In conclusion, the level of myocardial CD26 expression might be a predictive marker in HF patients.
